Micheli F, Martín AN, Aconapé JJ, Pardal M, Biller J. Tratado de Neurología Clínica. España: Médica Panamericana; 2003.

Tapia, R. Mecanismos celulares y moleculares de la neurodegeneración. Gac Méd Méx. 1998;134(6):685-703.

Kofler M, Schiefecker A, Ferger B. Cerebral taurine Levels are associated with brain edema and delayed cerebral infarction in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2015;23:321-9. DOI: 10.1007/s12028-015-0140-y

Pérez-Neri I, Diéguez-Campa CE. Taurine and aneurysmal subarachnoid hemorrhage prognosis, Postgraduate Medicine. 2018; 130(8): 669-72. DOI: 10.1080/00325481.2018.1533382

Hsieh YC, Guo C, Yalamanchili HK, Abreha M, Al-Ouran R, Li Y, et al. Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease. Cell Reports. 2019;29:301-16. DOI: 10.1016/j.celrep.2019.08.104

Guo C, Jeong HH, Hsieh YC, Klein HU, Bennett DA, De Jager PL. Tau Activates Transposable Elements in Alzheimer’s Disease. Cell Reports. 2018;23:2874-80. DOI: 10.1016/j.celrep.2018.05.004

Zhang X, Gao F, Dongdong W, Li C, Fu Y, He W, et al. Tau Pathology in Parkinson’s Disease. Front. Neurol. 2018;9:809. DOI: 10.3389/fneur.2018.00809

Henderson MX, Sengupta M, Trojanowski JQ, Lee VMY. Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease. Acta Neuropathologica Communications. 2019;7:183. DOI: 10.1186/s40478-019-0836-x